Elizabeth Plimack, MD, MS, attending physician, genitourinary cancer associate professor, Medical Oncology Director of Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a study that examined pembrolizumab in patients with urothelial cancer.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More